CFTR and cystic fibrosis: As a novel biomarker for therapeutic efficacy in CF patients focused on immune cells, we investigated if and how CFTR-dependent chloride channel activity in MNCs was modified by ivacaftor in the past [22] and by Orkambi® in the present study.